Navigation Links
FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
Date:4/9/2012

ATLANTA, Ga., April 9, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting at the inaugural Atlanta Clinical Cardiology Update (CCU), presented by the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University, April 13-14, 2012. The inaugural meeting will provide a new, needs-based and convenient forum for knowledge exchange between general and sub-specialist cardiologists across the spectrum of cardiovascular disease.  

FirstMark will showcase its new cardiovascular test PREvent at the meeting. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant stable CAD. The test is an exciting development in cardiovascular medicine, providing a simple solution for the huge unmet need of assessing CAD patients risk of near term myocardial infarction.

"One of the goals of the inaugural Atlanta CCU meeting is to give attendees the opportunity to catch up on recent clinical trials that are likely to influence practice, presented at conferences such as the American Heart Association and American College of Cardiology Scientific Sessions. The clinical trial for PREvent, was conducted at Emory University and presented at both of these conferences in oral Poster Presentations," said Thomas Silberg, President and CEO of GenWay Biotech. "The final data is quite remarkable, and we are excited for the opportunity to once again highlight the study and present the test."

About PREvent
PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

For additional information, please visit FirstMarkPREvent.com.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development
and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.



Media Contact: Deborah Moore GenWay Biotech, 858-458-0866, dmoore@genawaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
2. BIO-key(R) International Exhibiting at AABB TXPO
3. BIO-key(R) International Exhibiting at AABB TXPO
4. Exposure to young triggers new neuron creation in females exhibiting maternal behavior
5. Penn presents inaugural symposium on applied mathematics and computational science
6. Massague honored with inaugural AACR Distinguished Leadership Award in Breast Cancer Research
7. Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research
8. George M. Whitesides receives inaugural Dreyfus prize in the chemical sciences
9. George Whitesides accepts inaugural Dreyfus Prize in the Chemical Sciences
10. International AIDS Society announces inaugural recipients of innovative HIV research awards
11. Inaugural Herbert A. Fleisch ESCEO-IOF Medal is awarded to Professor Gerard Karsenty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... , ... September 23, 2019 , ... ... in Cambridge, MA, announce today that Holotype HLA and other Omixon products will ... of the American Society for Histocompatibility and Immunogenetics (ASHI) in Pittsburgh, ...
(Date:9/24/2019)... ... September 24, 2019 , ... Lajollacooks4u, San Diego’s premiere team-building ... five-star reviews on the popular travel review site, TripAdvisor. , Recent reviews call ... food” and “unique local experience.” These sentiments have not only led the way ...
(Date:9/17/2019)... ... September 17, 2019 , ... Last week, ... and engineers from the Medical University of Warsaw, met at the Presidential Palace ... in creating a neuroprosthetic system as part of an initiative called "Startups in ...
Breaking Biology News(10 mins):
(Date:9/30/2019)... , ... September 30, 2019 , ... ... science newsletter from Rigaku Corporation , is now available online on the ... X-ray based materials science, including X-ray diffraction, fluorescence and imaging, and presents articles, ...
(Date:9/24/2019)... ... 24, 2019 , ... Personalized Stem Cells, Inc ... for clinical trial sites and physician investigators. The clinical trial sites are ... , Clinical trial sites are currently located in San Diego and Los Angeles ...
(Date:9/17/2019)... ... 17, 2019 , ... Catalent, a global leader in clinical ... Asia Pacific (APAC) will present at the upcoming 3rd Annual Accelerating Clinical Trials ... On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will present “Singapore: APAC’s ...
(Date:9/17/2019)... WHITEHOUSE STATION, N.J. (PRWEB) , ... September 16, 2019 , ... ... tissue clearing reagents and kits that allow for the complete 3D characterization of tissues ... years, Visikol has transitioned into an imaging, image analysis and advanced cell culture focused ...
Breaking Biology Technology: